14 DICEMBRE 2024-TRAPANI: LA RIVOLUZIONE MULTIDISCIPLINARE NEL TRATTAMENTO DEL CARCINOMA DEL COLON-RETTO

Dicembre 10, 2024/da Luisa

OMISSION OF RADIOTHERAPY AFTER BREAST-CONSERVING SURGERY FOR WOMEN WITH BREAST CANCER WITH LOW CLINICAL AND GENOMIC RISK: 5-YEAR OUTCOMES OF IDEA

Dicembre 9, 2024/da Luisa

VENERDÌ 24– SABATO 25 GENNAIO 2025-NEGRAR DI VALPOLICELLA (VR) SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA

Dicembre 4, 2024/da Luisa

CALL TO ACTION-TEMPI CERTI DI ATTESA PER I PAZIENTI ONCOLOGICI: PDTA UNIFORMI E RETI EFFICIENTI

Dicembre 4, 2024/da Luisa

DURVALUMAB AFTER CHEMOTHERAPY IN LIMITED-STAGE SMALL-CELL LUNG CANCER.

Dicembre 3, 2024/da Luisa

NODAL BURDEN AND ONCOLOGIC OUTCOMES IN PATIENTS WITH RESIDUAL ISOLATED TUMOR CELLS AFTER NEOADJUVANT CHEMOTHERAPY (ypN0i+): THE OPBC-05/ICARO STUDY

Novembre 26, 2024/da Luisa

UGT1A1*28 POLYMORPHISM AND THE RISK OF TOXICITY AND DISEASE PROGRESSION IN PATIENTS WITH BREAST CANCER RECEIVING SACITUZUMAB GOVITECAN.

Novembre 18, 2024/da Luisa

CHARACTERISTICS AND CLINICAL OUTCOMES OF BREAST CANCER IN YOUNG BRCA CARRIERS ACCORDING TO TUMOR HISTOLOGY

Novembre 10, 2024/da Luisa

15 GENNAIO 2024, VERONA AIGOM-GIST AVANZATI: IL VALORE DELLA GESTIONE MULTIDISCIPLINARE DEL PAZIENTE

Novembre 9, 2024/da Luisa

NEOADJUVANT CHEMOTHERAPY WITH OXALIPLATIN AND FLUOROPYRIMIDINE VERSUS UPFRONT SURGERY FOR LOCALLY ADVANCED COLON CANCER: THE RANDOMIZED, PHASE III OPTICAL TRIAL.

Novembre 5, 2024/da Luisa

NEOADJUVANT DOCETAXEL, OXALIPLATIN, AND S-1 PLUS SURGERY AND ADJUVANT S-1 FOR RESECTABLE ADVANCED GASTRIC CANCER: UPDATED OVERALL SURVIVAL OUTCOMES FROM PHASE III PRODIGY.

Ottobre 28, 2024/da Luisa

ELACESTRANT (ORAL SELECTIVE ESTROGEN RECEPTOR DEGRADER) VERSUS STANDARD ENDOCRINE THERAPY FOR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER: RESULTS FROM THE RANDOMIZED PHASE III EMERALD TRIAL.

Ottobre 21, 2024/da Luisa
Carica di più